WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
WuXi Biologics (2269.HK) has received the Platinum Medal from EcoVadis Sustainability Rating for the second consecutive year, placing it among the top 1% of over 150,000 companies evaluated across 185 countries. The rating assesses seven management indicators across 21 sustainability criteria in four main areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.
As a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi Biologics has demonstrated strong commitment to sustainability and ESG excellence. The company participates in the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), earning multiple recognitions including:
- UNGC 20 Case Examples of Sustainable Development recognition
- MSCI AAA Rating
- Inclusion in Dow Jones Sustainability Indices
- Sustainalytics industry and regional ESG top-rated company status
- CDP Water Security 'A list' and Climate Change 'A-' score
- FTSE4Good Index Series constituent
- Hang Seng ESG 50 Index listing
WuXi Biologics (2269.HK) ha ricevuto la Medaglia d'Argento da EcoVadis Sustainability Rating per il secondo anno consecutivo, posizionandosi tra il 1% migliore di oltre 150.000 aziende valutate in 185 paesi. La valutazione analizza sette indicatori di gestione su 21 criteri di sostenibilità in quattro aree principali: Ambiente, Lavoro e Diritti Umani, Etica e Approvvigionamento Sostenibile.
In qualità di leader globale nel Contratto di Ricerca, Sviluppo e Produzione (CRDMO), WuXi Biologics ha dimostrato un forte impegno per la sostenibilità e l'eccellenza ESG. L'azienda partecipa al Global Compact delle Nazioni Unite (UNGC) e all'Iniziativa sulla Catena di Fornitura Farmaceutica (PSCI), guadagnando numerosi riconoscimenti tra cui:
- Riconoscimento UNGC con 20 Esempi di Sviluppo Sostenibile
- Valutazione MSCI AAA
- Inclusione negli Indici di Sostenibilità di Dow Jones
- Status di azienda top-rated secondo Sustainalytics a livello di settore e regionale
- Elenco 'A' di CDP Water Security e punteggio 'A-' per il Cambiamento Climatico
- Costituente della serie FTSE4Good Index
- Inclusione nell'Hang Seng ESG 50 Index
WuXi Biologics (2269.HK) ha recibido la Medalla de Platino de EcoVadis Sustainability Rating por segundo año consecutivo, colocándose entre el 1% superior de más de 150,000 empresas evaluadas en 185 países. La evaluación examina siete indicadores de gestión en 21 criterios de sostenibilidad en cuatro áreas principales: Medio Ambiente, Trabajo y Derechos Humanos, Ética y Compras Sostenibles.
Como una organización global líder en Investigación, Desarrollo y Fabricación por Contrato (CRDMO), WuXi Biologics ha demostrado un fuerte compromiso con la sostenibilidad y la excelencia ESG. La empresa participa en el Pacto Global de las Naciones Unidas (UNGC) y la Iniciativa de Cadena de Suministro Farmacéutico (PSCI), obteniendo múltiples reconocimientos, entre ellos:
- Reconocimiento UNGC con 20 Ejemplos de Desarrollo Sostenible
- Calificación MSCI AAA
- Inclusión en los Índices de Sostenibilidad de Dow Jones
- Estado de empresa mejor valorada según Sustainalytics a nivel industrial y regional
- Lista 'A' de CDP Water Security y puntuación 'A-' para Cambio Climático
- Miembro de la serie FTSE4Good Index
- Listado en el Índice ESG 50 de Hang Seng
우시 생명과학(WuXi Biologics) (2269.HK)는 에코바디스(EcoVadis) 지속 가능성 평가에서 두 번째 연속으로 플래티넘 메달을 수상하여 185개국에서 평가된 150,000개 이상의 기업 중 상위 1%에 자리잡았습니다. 이 평가는 환경, 노동 및 인권, 윤리, 지속 가능한 조달의 네 가지 주요 분야에서 21개의 지속 가능성 기준에 걸쳐 7개의 관리 지표를 평가합니다.
글로벌 계약 연구, 개발 및 제조 조직(CRDMO)의 선두주자로서, 우시 생명과학은 지속 가능성과 ESG 우수성에 대한 강한 의지를 보여주었습니다. 이 회사는 유엔 글로벌 컴팩트(UNGC) 및 제약 공급망 이니셔티브(PSCI)에 참여하며, 다음과 같은 여러 인정받은 성과를 이루었습니다:
- 지속 가능한 발전에 대한 UNGC 20 사례 예시 인정
- MSCI AAA 등급
- 다우존스 지속 가능성 지수 포함
- Sustainalytics 산업 및 지역 ESG 최고 등급 기업 지위
- CDP 물 안전성 'A 리스트' 및 기후 변화 'A-' 점수
- FTSE4Good 지수 시리즈 구성원
- 항셍 ESG 50 지수 등재
WuXi Biologics (2269.HK) a reçu la Médaille Platine de l'EcoVadis Sustainability Rating pour la deuxième année consécutive, se plaçant parmi le 1% des meilleures entreprises sur plus de 150 000 évaluées dans 185 pays. L'évaluation prend en compte sept indicateurs de gestion selon 21 critères de durabilité dans quatre domaines principaux : Environnement, Travail et Droits de l'Homme, Éthique et Approvisionnement Durable.
En tant qu'organisation mondiale de Recherche, Développement et Fabrication sous Contrat (CRDMO), WuXi Biologics a démontré un fort engagement en faveur de la durabilité et de l'excellence ESG. L'entreprise participe au Pacte Mondial des Nations Unies (UNGC) et à l'Initiative de la Chaîne d'Approvisionnement Pharmaceutique (PSCI), obtenant plusieurs reconnaissances, notamment :
- Reconnaissance UNGC avec 20 Exemples de Développement Durable
- Note MSCI AAA
- Inclusion dans les Indices de Durabilité de Dow Jones
- Statut d'entreprise hautement notée selon Sustainalytics, au niveau sectoriel et régional
- Liste 'A' de CDP Water Security et score 'A-' pour le Changement Climatique
- Membre de la série d'indices FTSE4Good
- Inscription dans l'Indice ESG 50 de Hang Seng
WuXi Biologics (2269.HK) hat zum zweiten Mal in Folge die Platinmedaille von EcoVadis Sustainability Rating erhalten und gehört damit zu den besten 1% von über 150.000 Unternehmen, die in 185 Ländern bewertet wurden. Die Bewertung beurteilt sieben Managementindikatoren anhand von 21 Nachhaltigkeitskriterien in vier Hauptbereichen: Umwelt, Arbeit und Menschenrechte, Ethik und nachhaltige Beschaffung.
Als führende globale Auftragsforschungs-, Entwicklungs- und Produktionsorganisation (CRDMO) hat WuXi Biologics ein starkes Engagement für Nachhaltigkeit und ESG-Exzellenz gezeigt. Das Unternehmen nimmt am Global Compact der Vereinten Nationen (UNGC) und an der Pharmaceutical Supply Chain Initiative (PSCI) teil und hat mehrere Auszeichnungen erhalten, darunter:
- UNGC 20 Fallbeispiele für nachhaltige Entwicklung
- MSCI AAA-Bewertung
- Einbeziehung in die Dow Jones Sustainability Indices
- Top-Bewertung von Sustainalytics in der Branche und regional
- CDP Water Security 'A-Liste' und Klimawandel 'A-' Bewertung
- Mitglied der FTSE4Good Index-Serie
- Auflistung im Hang Seng ESG 50 Index
- None.
- None.
- Ranked among the top
1% of more than 150,000 companies across 185 countries - Trusted by global partners for strong sustainability commitment
- Recognized as a leader in Green CRDMO, driving innovation for a healthier future
EcoVadis is a leading sustainability intelligence platform for global supply chains. Its sustainability ratings cover seven management indicators, across 21 sustainability criteria, under four main themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. The performance of companies is evaluated by assessing their policies, actions and results, and weighing inputs that come from third-party professionals and external stakeholders. In the newly published ratings scorecard, WuXi Biologics was ranked in the top
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to be once again recognized by EcoVadis with the Platinum Medal, which reflects our success in enhancing our sustainability capabilities. As a global leader in Green CRDMO, we are committed to continuously delivering ESG excellence, enabling partners worldwide to fulfill ESG goals, and jointly working with all stakeholders to promote responsible practices throughout the entire value chain."
As a participant in the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability, and has earned widespread recognition for its efforts. It was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-awarded-platinum-medal-by-ecovadis-sustainability-rating-for-second-consecutive-year-302378671.html
SOURCE WuXi Biologics
FAQ
What sustainability rating did WuXi Biologics (2269.HK) receive from EcoVadis in 2025?
How does WuXi Biologics rank among companies rated by EcoVadis?
What sustainability criteria does EcoVadis evaluate for WuXi Biologics?
What major sustainability initiatives is WuXi Biologics part of?
What ESG ratings and recognitions has WuXi Biologics received?
